Ảnh hưởng của việc bổ sung Docetaxel trước phẫu thuật vào Doxorubicin và Cyclophosphamide trước phẫu thuật: Kết quả sơ bộ từ Đề án B-27 của Dự án Phẫu thuật hỗ trợ quốc gia về ung thư vú và ruột
Tóm tắt
Từ khóa
#docetaxel #doxorubicin #cyclophosphamide #ung thư vú #đáp ứng lâm sàng #đáp ứng bệnh học #điều trị trước phẫu thuật #Dự án B-27Tài liệu tham khảo
Bear HD: Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 25:3,1998–12,
DeLena M, Varini M, Zucali R, et al: Multimodal treatment for locally advanced breast cancer: results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 4:229,1981–236,
Machiavelli MR, Romero AO, Pérez JE, et al: Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4:125,1998–131,
Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A:645,1994–652,
Fountzilas G, Athanassiades A, Giannakakis T, et al: A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 32A:47,1996–51,
Pivot X, Asmar L, Hortobagyi GN: The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer. Int J Oncol 15:381,1999–386,
Botti C, Vici P, Lopez M, et al: Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 181:202,1995–208,
Vermorken JB, Huizing MT, Liefting AJM, et al: High dose taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapy. Eur J Cancer 29A:S83,1993, (abstr 435)
Munzone E, Capri G, Demicheli R, et al: Activity of taxol (T) by 3 H infusion in breast cancer patients (pts) with clinical resistance to anthracyclines (A). Eur J Cancer 29A:S79,1993, (abstr 413)
Giap HB, Macey DJ, Podoloff DA: Development of a SPECT-based three-dimensional treatment planning system for radioimmunotherapy. J Nucl Med 36:1885,1995–1894,
Scholl SM, Pierga JY, Asselain B, et al: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969,1995–1975,
Gradishar WJ: Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer. Oncology 11:15,1997–18, (suppl 8)
Von Minckwitz G, Raab G, Schuette M, et al: Dose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2, M0)—primary endpoint analysis of the GEPARDUO-Study. Proc Am Soc Clin Oncol 21:43a,2002, (abstr 168)
Piccart MJ, Lohrisch C, Duchateau L, et al: Taxanes in the adjuvant treatment of breast cancer: why not yet? J Natl Cancer Inst Monogr 30:88,2001–95,
Swain SM, Sorace RA, Bagley CS, et al: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889,1987–3894,
Hutcheon AW, Heys SD, Miller ID, et al: Improvements in survival in patients receiving primary chemotherapy with docetaxel for breast cancer: A randomized controlled trial. Breast Cancer Res Treat 69:298,2001–298, (abstr 506)
Green MC, Buzdar AU, Smith T, et al: Weekly (wkly) paclitaxel (P) followed by FAC as primary systemic chemotherapy (PSC) of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q 3 wk) P therapy (tx) followed by FAC - final results of a prospective phase II randomized trial. Proc Am Soc Clin Oncol 21:35a,2002, (abstr 135)
Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845,1991–4852,
Steger GG, Wenzel C, Schmidinger M, et al: Predictive factors for a complete pathologic response (pCR) in primary breast cancer treated neoadjuvantly with a epirubicin/taxane + G-CSF regimen. Proc Am Soc Clin Oncol 20:39a,2001, (abstr 154)
Gianni L, Baselga J, Eiermann W, et al: First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21:34a,2002, (abstr 132)
Stearns V, Sing B, Tsangaris T, et al: A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9:124,2003–133,
Nabholtz JM, Pienkowski T, Mackey J, et al: Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 21:36a,2002, (abstr 141)
Albain KS, Green SJ, Ravdin PM, et al: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from Intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a,2002, (abstr 143)